Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update

Updated US guidance now recommends patients with early-stage BRCA1 or BRCA2, HER2-negative breast cancer with high risk of recurrence should be offered one year of adjuvant olaparib after completion of (neo)adjuvant chemotherapy and local treatment, including radiation.

Source:

Journal of Clinical Oncology